111 related articles for article (PubMed ID: 10776978)
1. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas.
Rege S; Safa AA; Chaiken L; Hoh C; Juillard G; Withers HR
Am J Clin Oncol; 2000 Apr; 23(2):164-9. PubMed ID: 10776978
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
[TBL] [Abstract][Full Text] [Related]
3. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.
Farber LA; Benard F; Machtay M; Smith RJ; Weber RS; Weinstein GS; Chalian AA; Alavi A; Rosenthal DI
Laryngoscope; 1999 Jun; 109(6):970-5. PubMed ID: 10369292
[TBL] [Abstract][Full Text] [Related]
4. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.
Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report.
Yao M; Smith RB; Hoffman HT; Funk GF; Lu M; Menda Y; Graham MM; Buatti JM
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):9-14. PubMed ID: 18930358
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Pai M; Park CH; Suh JH; Koh JH
Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation.
Greven KM; Williams DW; Keyes JW; McGuirt WF; Watson NE; Randall ME; Raben M; Geisinger KR; Cappellari JO
Cancer; 1994 Aug; 74(4):1355-9. PubMed ID: 8055460
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
11.
Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
[TBL] [Abstract][Full Text] [Related]
12. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer.
Wax MK; Myers LL; Gabalski EC; Husain S; Gona JM; Nabi H
Arch Otolaryngol Head Neck Surg; 2002 Jun; 128(6):703-7. PubMed ID: 12049568
[TBL] [Abstract][Full Text] [Related]
14.
Han EJ; O JH; Yoo IR; Kim YS; Kim MS; Kang JH; Choi WH
Hell J Nucl Med; 2017; 20(2):134-140. PubMed ID: 28697190
[TBL] [Abstract][Full Text] [Related]
15. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose.
Allal AS; Slosman DO; Kebdani T; Allaoua M; Lehmann W; Dulguerov P
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1295-300. PubMed ID: 15275712
[TBL] [Abstract][Full Text] [Related]
16. Positron-emission tomography for surveillance of head and neck cancer.
Ryan WR; Fee WE; Le QT; Pinto HA
Laryngoscope; 2005 Apr; 115(4):645-50. PubMed ID: 15805874
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses.
Anzai Y; Carroll WR; Quint DJ; Bradford CR; Minoshima S; Wolf GT; Wahl RL
Radiology; 1996 Jul; 200(1):135-41. PubMed ID: 8657901
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma.
Wong RJ; Lin DT; Schöder H; Patel SG; Gonen M; Wolden S; Pfister DG; Shah JP; Larson SM; Kraus DH
J Clin Oncol; 2002 Oct; 20(20):4199-208. PubMed ID: 12377963
[TBL] [Abstract][Full Text] [Related]
19. Surveillance for recurrent head and neck cancer using positron emission tomography.
Lowe VJ; Boyd JH; Dunphy FR; Kim H; Dunleavy T; Collins BT; Martin D; Stack BC; Hollenbeak C; Fletcher JW
J Clin Oncol; 2000 Feb; 18(3):651-8. PubMed ID: 10653881
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of F-18-FDG PET and ultrasound in the follow-up of patients with squamous cell cancer of the head and neck.
Goerres GW; Haenggeli CA; Allaoua M; Albrecht SR; Dulguerov P; Becker M; Allal AS; Lehmann W; Slosman DO
Nuklearmedizin; 2000 Dec; 39(8):246-50. PubMed ID: 11189902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
